U.S. markets closed

Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2020

Live Audio Webcast will be on May 12, 2020

SAN DIEGO, May 5, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2020 at 2:20 p.m. ET on Tuesday, May 12, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.

(PRNewsfoto/Neurocrine Biosciences, Inc.)

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease and endometriosis* and clinical development programs in multiple therapeutic areas including a gene therapy for Parkinson's disease, chorea in Huntington disease, congenital adrenal hyperplasia, epilepsy, uterine fibroids* and polycystic ovary syndrome*. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn(*in collaboration with AbbVie)

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-bank-of-america-merrill-lynch-health-care-conference-2020-301053318.html

SOURCE Neurocrine Biosciences, Inc.